TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:20
Calithera Biosciences Inc. ( CALA ) https://www.calithera.com
0.05USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-98.38%
CALA
SPY
36.71%
-99.93%
CALA
SPY
70.96%
-99.95%
CALA
SPY
262.36%
CALA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
0.25
-23.54
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
0.59
0.01
0.01
-270.13
0.00
0.80
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-244.87
100.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.4182
813.78
-81.58
0.22
Other Earnings and Cash Flow Stats:
Calithera Biosciences Inc. ( CALA ) Net Income TTM ($MM) is -109.52
Calithera Biosciences Inc. ( CALA ) Operating Income TTM ($MM) is -101.76
Calithera Biosciences Inc. ( CALA ) Owners' Earnings Annual ($MM) is -43.90
Calithera Biosciences Inc. ( CALA ) Current Price to Owners' Earnings ratio is -0.37
Calithera Biosciences Inc. ( CALA ) EBITDA TTM ($MM) is -101.63
Calithera Biosciences Inc. ( CALA ) EBITDA Margin is 0.00%
Capital Allocation:
Calithera Biosciences Inc. ( CALA ) has paid 0.00 dividends per share and bought back -0.127 million shares in the past 12 months
Calithera Biosciences Inc. ( CALA ) has reduced its debt by 0.357 million USD in the last 12 months
Capital Structure:
Calithera Biosciences Inc. ( CALA ) Interest-bearing Debt ($MM) as of last quarter is 1
Calithera Biosciences Inc. ( CALA ) Annual Working Capital Investments ($MM) are 5
Calithera Biosciences Inc. ( CALA ) Book Value ($MM) as of last quarter is 20
Calithera Biosciences Inc. ( CALA ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
Calithera Biosciences Inc. ( CALA ) has 25 million in cash on hand as of last quarter
Calithera Biosciences Inc. ( CALA ) has 7 million of liabilities due within 12 months, and long term debt 9 as of last quarter
Calithera Biosciences Inc. ( CALA ) has 4 common shares outstanding as of last quarter
Calithera Biosciences Inc. ( CALA ) has 22 million USD of preferred stock value
Academic Scores:
Calithera Biosciences Inc. ( CALA ) Altman Z-Score is -27.59 as of last quarter
Calithera Biosciences Inc. ( CALA ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Calithera Biosciences Inc. ( CALA ) largest shareholder is Arcus Capital Partners LLC owning 0 shares at 0.00 ($MM) value
Deepika Pakianathan(an insider) Sold 121333 shares of Calithera Biosciences Inc. ( CALA ) for the amount of $47319.87 on 2023-01-27
1.07% of Calithera Biosciences Inc. ( CALA ) is held by insiders, and 0.03% is held by institutions
Calithera Biosciences Inc. ( CALA ) went public on 2014-10-02
Other Calithera Biosciences Inc. ( CALA ) financial metrics:
FCF:-61.73
Unlevered Free Cash Flow:-3.39
EPS:11.61
Operating Margin:-244.87
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:277.05
Beta:0.22
Buffet's Owners Earnings:-43.90
Price to Owner's Earnings:-0.37
About Calithera Biosciences Inc. ( CALA ) :
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.